Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report
Furmonertinib may be effective for NSCLC patients with HER2 T8962A and L869R mutations and further studies are needed to confirm these results in prospective clinical trials.
Authors
- Ling Zhang (ORCID: https://orcid.org/0000-0001-8371-5252)
- Xin Yu (ORCID: https://orcid.org/0009-0000-6110-8822)
- Chunxiao Ni (ORCID: https://orcid.org/0000-0002-5312-3472)
- Jiaju Xu (ORCID: https://orcid.org/0000-0002-3633-0920)
- Yu Pang
Institutions
- Taian City Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.3389/fonc.2024.1440379
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.85